Investors & Media

Press Releases

Date Title and Summary Additional Formats
Toggle Summary ImmunoGen Reports Efficacy and Safety Data from a 46-Patient Cohort of Mirvetuximab Soravtansine in FRα-Positive Ovarian Cancer
Confirmed objective response rate of 44% and median progression-free survival of 6.7 months seen in cohort subset mirroring patient population selected for planned Phase 3 study. Company preparing to meet with FDA in early 3Q2016; targeting initiation of Phase 3 study in 4Q2016.
View HTML
Toggle Summary ImmunoGen, Inc. Announces Webcasts of Presentations at Upcoming Investor Conferences
WALTHAM, Mass. --(BUSINESS WIRE)-- ImmunoGen, Inc. (Nasdaq: IMGN), a biotechnology company developing targeted cancer therapeutics using its proprietary antibody-drug conjugate (ADC) technology, today announced that the following presentations by Company management at upcoming investor conferences
View HTML
Toggle Summary ImmunoGen Reports Third Quarter Fiscal Year 2016 Financial Results and Provides Corporate Update
− Conference call at 8:00 am ET today will include update on mirvetuximab soravtansine, the first folate receptor α (FRα)-targeting antibody-drug conjugate (ADC), including the design of the FORWARD I trial − WALTHAM, Mass. --(BUSINESS WIRE)-- ImmunoGen, Inc.
View HTML
Toggle Summary ImmunoGen Appoints Mark J. Enyedy as President and Chief Executive Officer
- Proven leader with deep experience building oncology businesses - WALTHAM, Mass. --(BUSINESS WIRE)-- ImmunoGen, Inc . (Nasdaq: IMGN) a biotechnology company developing targeted cancer therapeutics using its proprietary antibody-drug conjugate (ADC) technology, today announced that Mark J.
View HTML
Toggle Summary ImmunoGen Announces Initiation of Clinical Testing of First-in-Class IMGN779 for Acute Myeloid Leukemia
Novel CD33-targeting product candidate is the first antibody-drug conjugate (ADC) to employ an IGN, a new type of cancer-killing agent. Phase 1 study in acute myeloid leukemia (AML) is designed to efficiently inform the IMGN779 development pathway. WALTHAM, Mass.
View HTML
Toggle Summary ImmunoGen, Inc. Announces Conference Call to Discuss its Third Quarter Fiscal Year 2016 Financial Results
WALTHAM, Mass. --(BUSINESS WIRE)-- ImmunoGen, Inc. (Nasdaq: IMGN), a biotechnology company that develops novel anticancer therapeutics using its antibody-drug conjugate (ADC) technology, today announced that the Company will host a conference call at 8:00 a.m.
View HTML
Toggle Summary Daniel Junius to Retire as President and CEO of ImmunoGen, Inc.
- Successor Expected to be Announced Shortly - WALTHAM, Mass. --(BUSINESS WIRE)-- ImmunoGen, Inc. (Nasdaq: IMGN) a biotechnology company that develops targeted anticancer therapeutics using its antibody-drug conjugate (ADC) technology, today announced that Daniel Junius , age 63, has decided to
View HTML